PHLDA2 and osteosarcoma: The positive rates of RanBP9 and TSSC3 were 23% (3/13) and 38% (5/13), respectively, in osteosarcoma with metastasis, as well as 91% (61/67) and 88% (59/67), respectively, in osteosarcoma without metastasis.